TR199900504T2 - Treatment method for postmenopausal diseases, including osteoporosis - Google Patents

Treatment method for postmenopausal diseases, including osteoporosis

Info

Publication number
TR199900504T2
TR199900504T2 TR1999/00504T TR9900504T TR199900504T2 TR 199900504 T2 TR199900504 T2 TR 199900504T2 TR 1999/00504 T TR1999/00504 T TR 1999/00504T TR 9900504 T TR9900504 T TR 9900504T TR 199900504 T2 TR199900504 T2 TR 199900504T2
Authority
TR
Turkey
Prior art keywords
treatment method
including osteoporosis
postmenopausal
diseases
postmenopausal diseases
Prior art date
Application number
TR1999/00504T
Other languages
Turkish (tr)
Inventor
N. Bradbeer Jeremy
Gowen Maxine
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Publication of TR199900504T2 publication Critical patent/TR199900504T2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Osteoporoz tedavisi için yeni bir yöntem tanimlanmaktadir. Tercih edilen bilesim, Idoksifendir.A new method is described for the treatment of osteoporosis. The preferred composition is Idoxifene.

TR1999/00504T 1996-09-06 1997-09-03 Treatment method for postmenopausal diseases, including osteoporosis TR199900504T2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2543996P 1996-09-06 1996-09-06
US5066697P 1997-06-24 1997-06-24

Publications (1)

Publication Number Publication Date
TR199900504T2 true TR199900504T2 (en) 1999-06-21

Family

ID=26699738

Family Applications (2)

Application Number Title Priority Date Filing Date
TR1999/00506T TR199900506T2 (en) 1996-09-06 1997-09-03 New methods.
TR1999/00504T TR199900504T2 (en) 1996-09-06 1997-09-03 Treatment method for postmenopausal diseases, including osteoporosis

Family Applications Before (1)

Application Number Title Priority Date Filing Date
TR1999/00506T TR199900506T2 (en) 1996-09-06 1997-09-03 New methods.

Country Status (16)

Country Link
EP (2) EP0927029A4 (en)
JP (2) JP2002515047A (en)
KR (2) KR20000068472A (en)
CN (2) CN1236299A (en)
AR (1) AR008155A1 (en)
AU (2) AU4247397A (en)
BR (2) BR9711681A (en)
CA (2) CA2264943A1 (en)
CO (2) CO5070658A1 (en)
CZ (1) CZ76699A3 (en)
IL (1) IL128645A0 (en)
NO (2) NO991097D0 (en)
PL (2) PL332038A1 (en)
TR (2) TR199900506T2 (en)
TW (1) TW411273B (en)
WO (2) WO1998009619A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998034608A1 (en) * 1997-02-11 1998-08-13 Novo Nordisk A/S Methods for treatment or prophylaxis of menopausal symptoms
GB9827121D0 (en) * 1998-12-09 1999-02-03 Orion Corp Agent for lowering endothelin levels
DE19905961A1 (en) * 1999-02-12 2000-08-17 Stefan Neubauer Use of estrogens to treat cardiac insufficiency and left ventricular dysfunction following myocardial infarction
US6528681B2 (en) * 2000-04-05 2003-03-04 Bristol-Meyers Squibb Pharma Company Halogenated triphenylethylene derivatives as selective estrogen receptor modulators
IL145876A0 (en) 2000-10-17 2002-07-25 Pfizer Prod Inc Methods and kits for improving vascular health

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2196003A (en) * 1986-09-11 1988-04-20 Nat Res Dev Iodo-and bromo-tamoxifen derivatives
KR100326962B1 (en) * 1992-09-15 2002-12-02 메렐 파마슈티칼스 인크. Tamoxifen-Non Metabolic Clomiphene Analog for Treatment of Tolerant Tumor
US6197789B1 (en) * 1995-06-07 2001-03-06 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
US5681835A (en) * 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5604248A (en) * 1994-05-05 1997-02-18 Eli Lilly And Company Method for minimizing the uterotrophic effect of tamoxifen and tamoxifen analogs
US5470883A (en) * 1994-05-23 1995-11-28 Stromberg; Brent V. Method of treating peripheral vasoconstriction with tamoxifen citrate
HN1996000101A (en) * 1996-02-28 1997-06-26 Inc Pfizer COMBINED THERAPY FOR OSTEOPOROSIS
US6069175A (en) * 1996-11-15 2000-05-30 Pfizer Inc. Estrogen agonist/antagonists treatment of atherosclerosis

Also Published As

Publication number Publication date
AU4409797A (en) 1998-03-26
BR9711681A (en) 1999-08-24
EP0929216A1 (en) 1999-07-21
NO991097L (en) 1999-03-05
WO1998009519A1 (en) 1998-03-12
TW411273B (en) 2000-11-11
CO4920218A1 (en) 2000-05-29
NO991096D0 (en) 1999-03-05
AU4247397A (en) 1998-03-26
EP0929216A4 (en) 2001-04-04
BR9711676A (en) 1999-08-24
JP2002515046A (en) 2002-05-21
CN1236299A (en) 1999-11-24
CA2264775A1 (en) 1998-03-12
IL128645A0 (en) 2000-01-31
CZ76699A3 (en) 1999-08-11
PL332278A1 (en) 1999-08-30
PL332038A1 (en) 1999-08-16
AR008155A1 (en) 1999-12-09
EP0927029A1 (en) 1999-07-07
CA2264943A1 (en) 1998-03-12
CN1236313A (en) 1999-11-24
TR199900506T2 (en) 1999-07-21
KR20000068473A (en) 2000-11-25
JP2002515047A (en) 2002-05-21
EP0927029A4 (en) 2001-06-13
KR20000068472A (en) 2000-11-25
WO1998009619A1 (en) 1998-03-12
CO5070658A1 (en) 2001-08-28
NO991097D0 (en) 1999-03-05
NO991096L (en) 1999-03-05

Similar Documents

Publication Publication Date Title
TR199600096A2 (en) New compounds.
ATE291430T1 (en) TREATMENT OF POSTCLIMACTERIC WOMEN USING THE LOWEST DOSES OF ESTROGEN
TR199600786T1 (en) New pharmaceutical dosage forms taken by mouth.
TR199700092A2 (en) New, substituted oxazolidinones.
TR199501655A2 (en) New monocyclic-lactam compounds.
DE69602638T2 (en) Naphthyl compounds, intermediates, compositions and methods
TR199501527A2 (en) New peptide compounds.
FI991477A (en) Process for the preparation of tolterodine
ES2179273T3 (en) N-BENCIL-2-PHENYLINDOLS AS ESTROGENIC AGENTS.
NO983002L (en) Vitronectin receptor antagonists
MD1745B2 (en) 4,5-dimethyl-N-2-propenyl-2-(trimethylsilyl)-3-thiophencarboxamide, fungicidal composition on base thereof and method of plants diseases control
AR016981A2 (en) SYNTHETIC POLYPEPTIDES
DK0817851T5 (en) DNA encoding human papillomavirus type 18
DE69005172D1 (en) Dental cements.
BR9509741A (en) Compound and Compound Use
TR199900504T2 (en) Treatment method for postmenopausal diseases, including osteoporosis
NO986086D0 (en) Process for the preparation of 17-esters of 9 <alpha>, 21-dihalo-pregnan-11
DE69510545D1 (en) CCK OR GASTRINE MODULATING 5-HETEROCYCLICYL-1,5-BENZODIAZEPINE
TR199600778A2 (en) New sulfonamides.
DE69736180D1 (en) TREATMENT OF MANICAL DISEASES
ATE323493T1 (en) CONTROLLED RELEASE OF ANTIDEPRESSANTS
ATE107165T1 (en) USE OF MACROLACTONES AS ANTIALLERGICS.
DE69507628D1 (en) CONTROL DEVICE FOR OPTIMUM USE OF THE ENERGY GENERATED BY THE MAIN ENERGY SOURCE
SE9602416D0 (en) New forms of an organic salt of N'N-diacetylcystine
DE69526156T2 (en) Use of 1,3-undecadien-5-yne as a fragrance